Genprex, Inc. announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy for Genprex's pipeline of gene therapy drug candidates. Dr. Thornton-Jones has more than 25 years of experience in drug development and extensive experience in regulatory strategy and regulatory affairs.

Before joining Genprex, she was Vice President, Head of Regulatory Affairs and Project Team Lead at Tavanta Therapeutics, where Dr. Thornton-Jones established and directed robust regulatory strategies in support of early and late phase specialty products in the Tavanta portfolio. She lead the development and regulatory strategy for submission of regulatory documents to global regulatory agencies. Prior to that, Dr. Thornton-Jones was Vice President, Regulatory Affairs and Project Team Lead at Affinia Therapeutics, where she established and directed regulatory strategies in support of novel neurodevelopment and neuro-oncology gene therapy products for rare disease indications.

Dr. Thornton-Jones led strategic oversight for all program related activities to advance first-in-human clinical trials. She has also served in various other regulatory roles of increasing scope and responsibility, including at the Gene Therapy Program at the University of Pennsylvania'sPerelman School of Medicine, at AbbVie, Sanofi, and as a reviewer at the U.S. Food and Drug Administration, among others. Dr. Thornton-Jones holds a Ph.D. in Pharmacology and Toxicology and an M.S. and a B.S. in Biology, all from Virginia Commonwealth University.